3rd Year MBBS
Infection and Inflammation
Sympatholytic Drugs: Alpha, Beta and Mixed Adrenoceptor Antagonists
Connect receptor blockade with organ effects, clinical uses and major safety limitations for rapid revision.
1. THE TOPIC IN ONE CONNECTED FLOW
Sympatholytic adrenoceptor antagonists work by blocking α receptors, β receptors, or both. Their clinical effects can be predicted from the normal function of the receptor being blocked. The central flow is therefore: receptor target → physiological change → therapeutic benefit → important adverse effect or caution.
Labetalol and carvedilol combine α₁-mediated vasodilation with β blockade, so peripheral resistance and sympathetic cardiac stimulation fall together.
2. KEY CLINICAL CONNECTIONS
α₁ blockade → vasodilation → ↓ peripheral vascular resistance → lower blood pressure.
The same loss of reflex vasoconstriction on standing → postural hypotension; non-selective α blockade may cause more reflex tachycardia because α₂ feedback is also lost.
β₁ blockade → slower heart + reduced contractility and renin → useful cardiovascular effects.
β₂ blockade → loss of bronchodilation and some metabolic/vascular responses → caution in asthma, diabetes and peripheral arterial disease.
Prostatic symptoms → preferential α₁A blockade with tamsulosin → urinary smooth-muscle relaxation with relatively less vascular effect.
Stable chronic heart failure → selected agents such as carvedilol, bisoprolol or appropriate long-acting metoprolol → reduced harmful chronic sympathetic stimulation.
3. AIM HIGH-YIELD INTEGRATION REVIEW
Beta blockers are useful in stable chronic heart failure, but their negative inotropic effect can worsen acute decompensated heart failure. The clinical state determines whether the same pharmacological action is beneficial or harmful.